Scott Helton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Scott Helton has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Adnan Alseidi
Department of Surgery, University of California San Francisco, San Francisco, CA 94143, USA
10 shared publications - Flavio G. Rocha
Division of Surgical Oncology, Oregon Health & Science University
10 shared publications - Vincent J. Picozzi
Virginia Mason Medical Center, Seattle, WA
8 shared publications Bruce S. Lin
Virginia Mason Medical Center, Seattle, WA
5 shared publications- John Bart Rose
Department of Surgery, University of Alabama at Birmingham, 1824 6th Avenue S., Birmingham, AL 35233, USA
5 shared publications Alicia M Edwards
Virginia Mason Medical Center, Seattle, WA
4 shared publications
Latest Publications
- 1 April 2018
- Published by AME Publishing Company in Annals of Pancreatic Cancer
- Vol. 1  (1) , AB059
AB059. P031. Outcomes of pylorus-preserving versus conventional pancreaticoduodenectomy in the era of enhanced recovery: a single-institution experience
Background: Recent randomized trials and meta-analysis have demonstrated an increased incidence of delayed gastric emptying (DGE) with pylorus preserving pancreaticoduodenectomy (PP) compared to conventional Whipple (CW). At our high-volume referral center, both techniques are performed according to individual surgeon preference, with perioperative care standardized by an enhanced recovery [Electronic Residency Application Service (ERAS)] protocol—a setup akin to an expertise-based trial. We therefore set out to compare the morbidity experience of patients undergoing PP and CW at our institution. Methods: Following IRB approval, we accessed our prospectively collected complications database for patients undergoing PP and CW after the institution of our ERAS protocol. This protocol included routine use of epidural analgesia, limited opioids, early ambulation and no routine nasogastric tubes. We compared their preoperative characteristics and postoperative complications using student t-tests, chi-square tests, Wilcoxon rank-sum test, and univariate logistic regression to identify variables associated with DGE. We performed a multivariate logistic regression to adjust for confounding variables and isolate the effect of pylorus preservation on DGE. Results: In total, 133 CW and 147 PP were identified during the study period. Their preoperative characteristics were similar, but more patients in the CW group underwent a portal vein resection (24.8% vs. 14.3% for CW and PP respectively, P=0.026). Moreover, 21.7% and 17.7% of patients developed DGE in the CW and PP groups respectively (P=0.457). DGE was associated with diabetes (OR, 2.9; 95% CI, 1.43–6.06; P=0.03) but not body mass index (BMI) (OR, 1.04; 95% CI, 0.98–1.11; P=0.177) at univariate logistic regression. Patients that developed a pancreatic fistula had higher odds of DGE (OR, 2.9; 95% CI, 1.58–5.46; P=0.001). At multivariate logistic regression, there remained no association between PP and DGE. Conclusions: The morbidity of patients undergoing CW and PP by expert surgeons under an ERAS protocol was similar at our institution.
- 1 April 2018
- Published by AME Publishing Company in Annals of Pancreatic Cancer
- Vol. 1  (1) , AB059
AB059. P031. Outcomes of pylorus-preserving versus conventional pancreaticoduodenectomy in the era of enhanced recovery: a single-institution experience
Background: Recent randomized trials and meta-analysis have demonstrated an increased incidence of delayed gastric emptying (DGE) with pylorus preserving pancreaticoduodenectomy (PP) compared to conventional Whipple (CW). At our high-volume referral center, both techniques are performed according to individual surgeon preference, with perioperative care standardized by an enhanced recovery [Electronic Residency Application Service (ERAS)] protocol—a setup akin to an expertise-based trial. We therefore set out to compare the morbidity experience of patients undergoing PP and CW at our institution. Methods: Following IRB approval, we accessed our prospectively collected complications database for patients undergoing PP and CW after the institution of our ERAS protocol. This protocol included routine use of epidural analgesia, limited opioids, early ambulation and no routine nasogastric tubes. We compared their preoperative characteristics and postoperative complications using student t-tests, chi-square tests, Wilcoxon rank-sum test, and univariate logistic regression to identify variables associated with DGE. We performed a multivariate logistic regression to adjust for confounding variables and isolate the effect of pylorus preservation on DGE. Results: In total, 133 CW and 147 PP were identified during the study period. Their preoperative characteristics were similar, but more patients in the CW group underwent a portal vein resection (24.8% vs. 14.3% for CW and PP respectively, P=0.026). Moreover, 21.7% and 17.7% of patients developed DGE in the CW and PP groups respectively (P=0.457). DGE was associated with diabetes (OR, 2.9; 95% CI, 1.43–6.06; P=0.03) but not body mass index (BMI) (OR, 1.04; 95% CI, 0.98–1.11; P=0.177) at univariate logistic regression. Patients that developed a pancreatic fistula had higher odds of DGE (OR, 2.9; 95% CI, 1.58–5.46; P=0.001). At multivariate logistic regression, there remained no association between PP and DGE. Conclusions: The morbidity of patients undergoing CW and PP by expert surgeons under an ERAS protocol was similar at our institution.
- 1 April 2018
- Published by AME Publishing Company in Annals of Pancreatic Cancer
- Vol. 1  (1) , AB016
AB016. S016. Lymphadenectomy in resected node-negative pancreatic cancer: are some patients being understaged?
Background: Validated benchmarks for adequate lymphadenectomy (LAD) are well established for gastric and colon cancers to avoid stage-migration. Although a harvest of 15 nodes has been proposed for pancreas cancer, this number has not been confirmed in a large, multi-institutional setting. We examined the relationship between LAD and survival in node-negative patients having undergone pancreatectomy for pancreatic adenocarcinoma to identify whether some patients with low lymph node counts are understaged. Methods: We identified all node-negative patients undergoing pancreaticoduodenectomy (PD) and distal pancreatectomy (DP) for pancreatic adenocarcinoma within the National Cancer Database (NCDB) between 2004 and 2014. We excluded patients with clinical or pathologic M1 disease, as well as patients that died within 90 days from surgery and those with no data on lymph node harvest. Univariate and multivariate quantile regression were used to identify the effect of lymph node harvests and other patient and tumor-specific variables on survival. Results: We identified 7,329 and 2,071 patients undergoing PD and DP respectively staged as pN0 and meeting inclusion criteria. Median survival was 21.5 (95% CI, 21.1–21.9) and 21.2 (95% CI, 20.1–22.1) months in the PD and DP groups, respectively. In the PD group, LAD ≥15 was not associated with a higher median survival [21.6 (95% CI, 20.9–22.4) and 21.3 (95% CI, 20.7–21.9) months in the Conclusions: We did not identify a group of patients that were understaged as a function of low lymph nodes harvests. A benchmark of 15 lymph nodes for pancreas cancer cannot be recommended as a quality measure.
- 1 April 2018
- Published by AME Publishing Company in Annals of Pancreatic Cancer
- Vol. 1  (1) , AB016
AB016. S016. Lymphadenectomy in resected node-negative pancreatic cancer: are some patients being understaged?
Background: Validated benchmarks for adequate lymphadenectomy (LAD) are well established for gastric and colon cancers to avoid stage-migration. Although a harvest of 15 nodes has been proposed for pancreas cancer, this number has not been confirmed in a large, multi-institutional setting. We examined the relationship between LAD and survival in node-negative patients having undergone pancreatectomy for pancreatic adenocarcinoma to identify whether some patients with low lymph node counts are understaged. Methods: We identified all node-negative patients undergoing pancreaticoduodenectomy (PD) and distal pancreatectomy (DP) for pancreatic adenocarcinoma within the National Cancer Database (NCDB) between 2004 and 2014. We excluded patients with clinical or pathologic M1 disease, as well as patients that died within 90 days from surgery and those with no data on lymph node harvest. Univariate and multivariate quantile regression were used to identify the effect of lymph node harvests and other patient and tumor-specific variables on survival. Results: We identified 7,329 and 2,071 patients undergoing PD and DP respectively staged as pN0 and meeting inclusion criteria. Median survival was 21.5 (95% CI, 21.1–21.9) and 21.2 (95% CI, 20.1–22.1) months in the PD and DP groups, respectively. In the PD group, LAD ≥15 was not associated with a higher median survival [21.6 (95% CI, 20.9–22.4) and 21.3 (95% CI, 20.7–21.9) months in the Conclusions: We did not identify a group of patients that were understaged as a function of low lymph nodes harvests. A benchmark of 15 lymph nodes for pancreas cancer cannot be recommended as a quality measure.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35  (15_suppl) , e15771
Extended neoadjuvant chemotherapy (CT) in borderline resectable pancreatic cancer (BRPC): Updated results.
E15771 Background: Optimum therapy (Rx) for BRPC is unknown. Since 2008, we have used neoadjuvant Rx with extended course chemotherapy (CT) but not routine neoadjuvant chemoradiation (CRT). Initial results were presented in 2013 (Rose et.al. J Clin Oncolabstr 4043). We present updated findings here. Methods: Patients (pts) were prospectively identified in our institutional PC database. Inclusion criteria: 1) bx-proven PC; 2) radiographic staging per AHPBA/NCCN criteria; 3) no prior Rx; 4) negative staging laparoscopy whenever feasible; 5) all neoadjuvant Rx at our institution, 6) followup ≥ 24 weeks (wks) from initial Rx . Unless disease progression or Rx intolerance noted, pts received gemcitabine/docetaxel (G/D) as neoadjuvant CT x 24 weeks . At that time, all pts felt likely to achieve R0 resection offered surgery; other pts offered 5FU –based CRT if medically fit. Results evaluated by "intent to treat". Results: Among 129 pts, characteristics include median age 66 yrs (range 33-88 yrs), ECOG PS 0/1/2+ 86/36/7, 97%/43% venous /arterial involvement. 78% (101/129) pts completed ≥80% intended CT; 38% (6/16) pts age > 80 and /or ECOG 2+ (p < 0.01) 51% (66/129) pts were resected (44 R0, 22 R1 ≤ 1 mm margin ). 49% (63/129) pts were not (24 disease progression, 17 surgeon decision (anatomy/safety), 11 Rx toxicity/ comorbidity, 6 unresectable at surgery, 5 pt withdrawal). 45% (31/66) and 23% (16/66) resected pts received postop CRT/CT respectively. Median f/u is 47 months (mo). 58% (38/66) resected pts recurred: 18% (12/66) local, 41% (27/66) systemic. For resected pts, median PFS is 25.0 (95% CI: 16.2-32.7) mo, median OS is 37.6 (95% CI: 27.4-58.5) mo. 5-yr OS is 28% ( 95% CI :14-44%). Median OS for non-resected pts is 13.1 (95% CI 10.9-16.9) mo .Median OS for all pts is 22.1 (95% CI: 18.7-28.4) mo. Conclusions: 1.Our series is distinctive with respect to size, use of laparoscopic staging and neoadjuvant G/D CT as standards,and median f/u 2. Pt selection is key; e.g.approach suboptimal for pts > 80 yrs/ ECOG PS 2+ 3. Reported OS compares favorably with other BRPC and de novo resectable PC cooperative group results 4. Detailed analysis of our study (e.g. prognostic factors) will aid future clinical research in BRPC.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35  (15_suppl) , e15771
Extended neoadjuvant chemotherapy (CT) in borderline resectable pancreatic cancer (BRPC): Updated results.
E15771 Background: Optimum therapy (Rx) for BRPC is unknown. Since 2008, we have used neoadjuvant Rx with extended course chemotherapy (CT) but not routine neoadjuvant chemoradiation (CRT). Initial results were presented in 2013 (Rose et.al. J Clin Oncolabstr 4043). We present updated findings here. Methods: Patients (pts) were prospectively identified in our institutional PC database. Inclusion criteria: 1) bx-proven PC; 2) radiographic staging per AHPBA/NCCN criteria; 3) no prior Rx; 4) negative staging laparoscopy whenever feasible; 5) all neoadjuvant Rx at our institution, 6) followup ≥ 24 weeks (wks) from initial Rx . Unless disease progression or Rx intolerance noted, pts received gemcitabine/docetaxel (G/D) as neoadjuvant CT x 24 weeks . At that time, all pts felt likely to achieve R0 resection offered surgery; other pts offered 5FU –based CRT if medically fit. Results evaluated by "intent to treat". Results: Among 129 pts, characteristics include median age 66 yrs (range 33-88 yrs), ECOG PS 0/1/2+ 86/36/7, 97%/43% venous /arterial involvement. 78% (101/129) pts completed ≥80% intended CT; 38% (6/16) pts age > 80 and /or ECOG 2+ (p < 0.01) 51% (66/129) pts were resected (44 R0, 22 R1 ≤ 1 mm margin ). 49% (63/129) pts were not (24 disease progression, 17 surgeon decision (anatomy/safety), 11 Rx toxicity/ comorbidity, 6 unresectable at surgery, 5 pt withdrawal). 45% (31/66) and 23% (16/66) resected pts received postop CRT/CT respectively. Median f/u is 47 months (mo). 58% (38/66) resected pts recurred: 18% (12/66) local, 41% (27/66) systemic. For resected pts, median PFS is 25.0 (95% CI: 16.2-32.7) mo, median OS is 37.6 (95% CI: 27.4-58.5) mo. 5-yr OS is 28% ( 95% CI :14-44%). Median OS for non-resected pts is 13.1 (95% CI 10.9-16.9) mo .Median OS for all pts is 22.1 (95% CI: 18.7-28.4) mo. Conclusions: 1.Our series is distinctive with respect to size, use of laparoscopic staging and neoadjuvant G/D CT as standards,and median f/u 2. Pt selection is key; e.g.approach suboptimal for pts > 80 yrs/ ECOG PS 2+ 3. Reported OS compares favorably with other BRPC and de novo resectable PC cooperative group results 4. Detailed analysis of our study (e.g. prognostic factors) will aid future clinical research in BRPC.
- 1 February 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35  (4_suppl) , 365
Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ± pamrevlumab (P) as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).
365 Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by dense stroma and connective tissue growth factor (CTGF) overexpression. Although prolonged overall survival (OS) can be achieved through resection, only approximately 15% to 20% of patients are treated with surgery. Previously, pamrevlumab (P), a fully human monoclonal antibody blocking CTGF, was combined with gemcitabine/erlotinib (G/E) in a study of advanced PDAC. P plasma levels of > 150 μg/mL and low baseline CTGF levels resulted in prolonged OS. We hypothesize that neoadjuvant (NA) treatment of LAPC with P + G/nab-paclitaxel (NP) may alter LAPC’s stroma, increase R0 resectability, and improve OS similar to that of patients resectable at presentation. Methods: LAPC subjects, confirmed by NCCN criteria and staging laparoscopy, were randomized 2:1 to G/NP ± P for 6-cycle/24-week treatment. Safety and efficacy (resection rate, OS, progression-free survival, tumor response) were assessed. Resection was performed in subjects who met protocol-defined criteria with no contraindications. Results: As of 26 Sep 2016, 25 subjects were enrolled. Of 14 subjects in Arm A (G/NP + P), 7 completed, 2 discontinued. Of 11 subjects in Arm B (G/NP), 4 completed, 4 discontinued. 6 subjects (43%) in Arm A and 4 (36%) in Arm B experienced SAEs; no P-related SAEs were reported. Out of 7 eligible Arm A subjects, 3 were not resected. Successful resection was achieved in 4 Arm A subjects (3 R0, 1 R1) and 1 Arm B subject (R0) (Table). Conclusions: The combination of G/NP + P is feasible and well-tolerated with no incremental safety signals in this study. The addition of P suggests a trend toward increased resectability among LAPC subjects. Clinical trial information: NCT02210559. [Table: see text]
- 1 February 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35  (4_suppl) , 365
Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ± pamrevlumab (P) as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).
365 Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by dense stroma and connective tissue growth factor (CTGF) overexpression. Although prolonged overall survival (OS) can be achieved through resection, only approximately 15% to 20% of patients are treated with surgery. Previously, pamrevlumab (P), a fully human monoclonal antibody blocking CTGF, was combined with gemcitabine/erlotinib (G/E) in a study of advanced PDAC. P plasma levels of > 150 μg/mL and low baseline CTGF levels resulted in prolonged OS. We hypothesize that neoadjuvant (NA) treatment of LAPC with P + G/nab-paclitaxel (NP) may alter LAPC’s stroma, increase R0 resectability, and improve OS similar to that of patients resectable at presentation. Methods: LAPC subjects, confirmed by NCCN criteria and staging laparoscopy, were randomized 2:1 to G/NP ± P for 6-cycle/24-week treatment. Safety and efficacy (resection rate, OS, progression-free survival, tumor response) were assessed. Resection was performed in subjects who met protocol-defined criteria with no contraindications. Results: As of 26 Sep 2016, 25 subjects were enrolled. Of 14 subjects in Arm A (G/NP + P), 7 completed, 2 discontinued. Of 11 subjects in Arm B (G/NP), 4 completed, 4 discontinued. 6 subjects (43%) in Arm A and 4 (36%) in Arm B experienced SAEs; no P-related SAEs were reported. Out of 7 eligible Arm A subjects, 3 were not resected. Successful resection was achieved in 4 Arm A subjects (3 R0, 1 R1) and 1 Arm B subject (R0) (Table). Conclusions: The combination of G/NP + P is feasible and well-tolerated with no incremental safety signals in this study. The addition of P suggests a trend toward increased resectability among LAPC subjects. Clinical trial information: NCT02210559. [Table: see text]
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34  (15_suppl) , e15693
Overall survival (OS) in stage II resected pancreatic cancer ( PC) using gemcitabine (Gem)/taxane adjuvant therapy (Rx): a single-institution experience.
E15693 Background: Adjuvant rx using single-agent gem in resected PC typically has produced median / 5-year (yr) survivals of 18-22 months (mo)/ 10%, respectively. As taxanes added to gem improved OS in advanced PC, we studied this combination in the above setting. Methods: Patients (pts) with primary resected PC were identified from our institutional pancreaticobiliary database and tumor registry. Inclusion criteria were 1) no tumor recurrence prior to adjuvant rx, 2) gem/taxane given as initial adjuvant rx and 3) all adjuvant rx given at our institution. Results: 57 pts from 2010-2015 were identified per the above criteria. All pts received gem/docetaxel as adjuvant Rx. Pt characteristics were median age 65 yrs, ECOG PS 0/1 68%/30%. Path characteristics included AJCC stage I/IIA/IIB 3(5%)/15/(26%)/39 (68%), median tumor size 2.8 cm,non- poor/poor diff tumor grade 46%/54%, node positive 68%, margin positive ( < 1mm) 49%. 9/57 (16%) pts had postop week 8 Ca 19.9 > 200U/mL (range < 3-4526). With 42 mo median f/u, median DFS/OS for all pts is 30.5/52.3mo (95% CI 20.7-NR mo/ 31.0-NR mo). 5-yr actuarial OS is 49% (95% CI 29-66%, Kaplan -Meier). 2/57 pts are currently on Rx; 46/55 (84%) received ≥ 12 cycles adjuvant Rx ; 36/55 (65%) received chemoradiation (CRT) post completion adjuvant Rx. Reasons for no CRT included disease progression/death (10 pts), comorbidity/MD recommendation (6 pts), pt choice(3 pts). Both ≥ 12 cycles adjuvant Rx (HR 0.26,95% CI 0.10-0.69) and CRT ( HR 0.37, 95% CI 0.15-0.90) were associated with improved OS. 26/57 (46%) pts have recurred; 2(3%) local, 22(37%) distant , 2(3%) combined. 18/59 (32%) pts were hospitalized during adjuvant Rx; no Rx-related deaths occurred. Conclusions: 1) gem/taxane combination Rx can be successfully given as adjuvant Rx. 2) Median and 5-yr OS shown here compares favorably with use of single-agent adjuvant Rx both as published previously by our institution and with outside literature reports, particularly considering pt stage (95% stage II) and other pt path characteristics . 3) Improved OS was seen with ≥ 12 cycles adjuvant Rx and CRT.4) Further investigation into gem/taxane adjuvant Rx in resected PC is supported by these data.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34  (15_suppl) , e15693
Overall survival (OS) in stage II resected pancreatic cancer ( PC) using gemcitabine (Gem)/taxane adjuvant therapy (Rx): a single-institution experience.
E15693 Background: Adjuvant rx using single-agent gem in resected PC typically has produced median / 5-year (yr) survivals of 18-22 months (mo)/ 10%, respectively. As taxanes added to gem improved OS in advanced PC, we studied this combination in the above setting. Methods: Patients (pts) with primary resected PC were identified from our institutional pancreaticobiliary database and tumor registry. Inclusion criteria were 1) no tumor recurrence prior to adjuvant rx, 2) gem/taxane given as initial adjuvant rx and 3) all adjuvant rx given at our institution. Results: 57 pts from 2010-2015 were identified per the above criteria. All pts received gem/docetaxel as adjuvant Rx. Pt characteristics were median age 65 yrs, ECOG PS 0/1 68%/30%. Path characteristics included AJCC stage I/IIA/IIB 3(5%)/15/(26%)/39 (68%), median tumor size 2.8 cm,non- poor/poor diff tumor grade 46%/54%, node positive 68%, margin positive ( < 1mm) 49%. 9/57 (16%) pts had postop week 8 Ca 19.9 > 200U/mL (range < 3-4526). With 42 mo median f/u, median DFS/OS for all pts is 30.5/52.3mo (95% CI 20.7-NR mo/ 31.0-NR mo). 5-yr actuarial OS is 49% (95% CI 29-66%, Kaplan -Meier). 2/57 pts are currently on Rx; 46/55 (84%) received ≥ 12 cycles adjuvant Rx ; 36/55 (65%) received chemoradiation (CRT) post completion adjuvant Rx. Reasons for no CRT included disease progression/death (10 pts), comorbidity/MD recommendation (6 pts), pt choice(3 pts). Both ≥ 12 cycles adjuvant Rx (HR 0.26,95% CI 0.10-0.69) and CRT ( HR 0.37, 95% CI 0.15-0.90) were associated with improved OS. 26/57 (46%) pts have recurred; 2(3%) local, 22(37%) distant , 2(3%) combined. 18/59 (32%) pts were hospitalized during adjuvant Rx; no Rx-related deaths occurred. Conclusions: 1) gem/taxane combination Rx can be successfully given as adjuvant Rx. 2) Median and 5-yr OS shown here compares favorably with use of single-agent adjuvant Rx both as published previously by our institution and with outside literature reports, particularly considering pt stage (95% stage II) and other pt path characteristics . 3) Improved OS was seen with ≥ 12 cycles adjuvant Rx and CRT.4) Further investigation into gem/taxane adjuvant Rx in resected PC is supported by these data.
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150  (4) , S1250-S1251
Tu1444 Comparative Analysis of Techniques and Outcomes for Resection of Benign or Low-Grade Neoplasms in the Duodenum
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150  (4) , S1250-S1251
Tu1444 Comparative Analysis of Techniques and Outcomes for Resection of Benign or Low-Grade Neoplasms in the Duodenum
- 1 February 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34  (4_suppl) , 457
Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ±FG-3019 as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).
457 Background: Curative therapy for PDAC is currently achievable through resection only, but ≤ 15% of patients are candidates for surgery. FG-3019, a recombinant human mAb to connective tissue growth factor (CTGF), plus gemcitabine (G) significantly reduced tumor growth, increased apoptosis and improved survival vs G alone in the KPC mouse model. Higher FG-3019 exposure and lower baseline (BL) CTGF were independently and significantly associated with improved overall median and 1-year survival (OS) in a Ph2a trial with G and erlotinib in stage 3 or 4 PDAC. Neoadjuvant treatment of LAPC with FG-3019 combined with multidrug therapy may change the fibrotic character of LAPC and thus may make it amenable to surgical resection and potentially improve OS. Methods: Patients with unresectable LAPC (confirmed by laparoscopy) are randomized to G/NP ±FG-3019 for 6-cycle/24-week treatment. Safety, efficacy, PK and changes in CT, PET, & CA19.9 from BL through end of treatment (EOT) are assessed. Up to 4 endoscopic ultrasound (EUS) guided core biopsies are collected at BL. Protein microarrays of pre- and post-treatment biopsies are prepared from tumor and stromal cells isolated by laser capture microdissection. Surgical exploration is performed in subjects who achieved the protocol-defined criteria for possible resection. Results: To date, 11 subjects were enrolled with 5 randomized to +FG-3019 arm. There were no complications from laparoscopy or EUS core biopsies that were clinically significant or delayed dosing. Per investigator assessment, no FG-3019-related SAEs were reported, nor any identified toxicity suspected from combination of FG-3019 with chemotherapy. Overall, CA19.9 mean change from BL was −62.7% at Week 8 (n = 8), and target lesions were reduced by 20.6% (n = 6) at Week 16. Three out of 4 subjects had PET SUVmax reductions of ≥ 30% at EOT. Additional data from protein microarrays will be presented. Conclusions: Based on the limited data collected so far, this trial design is feasible and the G/NP +FG-3019 combination is well-tolerated and appears to be active. Summary results on surgical exploration of subjects will be provided later. Clinical trial information: NCT02210559.
- 1 February 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34  (4_suppl) , 457
Randomized, open-label trial of gemcitabine/nab-paclitaxel (G/NP) ±FG-3019 as neoadjuvant chemotherapy in locally advanced, unresectable pancreatic cancer (LAPC).
457 Background: Curative therapy for PDAC is currently achievable through resection only, but ≤ 15% of patients are candidates for surgery. FG-3019, a recombinant human mAb to connective tissue growth factor (CTGF), plus gemcitabine (G) significantly reduced tumor growth, increased apoptosis and improved survival vs G alone in the KPC mouse model. Higher FG-3019 exposure and lower baseline (BL) CTGF were independently and significantly associated with improved overall median and 1-year survival (OS) in a Ph2a trial with G and erlotinib in stage 3 or 4 PDAC. Neoadjuvant treatment of LAPC with FG-3019 combined with multidrug therapy may change the fibrotic character of LAPC and thus may make it amenable to surgical resection and potentially improve OS. Methods: Patients with unresectable LAPC (confirmed by laparoscopy) are randomized to G/NP ±FG-3019 for 6-cycle/24-week treatment. Safety, efficacy, PK and changes in CT, PET, & CA19.9 from BL through end of treatment (EOT) are assessed. Up to 4 endoscopic ultrasound (EUS) guided core biopsies are collected at BL. Protein microarrays of pre- and post-treatment biopsies are prepared from tumor and stromal cells isolated by laser capture microdissection. Surgical exploration is performed in subjects who achieved the protocol-defined criteria for possible resection. Results: To date, 11 subjects were enrolled with 5 randomized to +FG-3019 arm. There were no complications from laparoscopy or EUS core biopsies that were clinically significant or delayed dosing. Per investigator assessment, no FG-3019-related SAEs were reported, nor any identified toxicity suspected from combination of FG-3019 with chemotherapy. Overall, CA19.9 mean change from BL was −62.7% at Week 8 (n = 8), and target lesions were reduced by 20.6% (n = 6) at Week 16. Three out of 4 subjects had PET SUVmax reductions of ≥ 30% at EOT. Additional data from protein microarrays will be presented. Conclusions: Based on the limited data collected so far, this trial design is feasible and the G/NP +FG-3019 combination is well-tolerated and appears to be active. Summary results on surgical exploration of subjects will be provided later. Clinical trial information: NCT02210559.
- 1 February 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34  (4_suppl) , 362
Comparative analysis of resected duodenal and ampullary adenocarcinoma.
362 Background: Duodenal and ampullary adenocarcinomas are rare gastrointestinal cancers that share similar anatomic location and treatment strategy. We report a single-institution experience regarding the association between clinicopathologic features, treatment, and survival outcomes. Methods: A retrospective review of all patients resected with curative intent for duodenal adenocarcinoma (DUO) between 2005-2015 and ampullary adenocarcinoma (AMP) between 2011-2015 at VMMC was performed. For AMP, histologic subtyping into intestinal (IT) and pancreatobiliary (PB) phenotypes was determined. Demographic and clinicopathologic parameters were compared between DUO and AMP patients using Chi-square test. Overall survival was calculated using Kaplan-Meier analysis and prognostic factors were identified by univariate Cox regression. Results: Patients with DUO (n = 44) presented at higher T-stage (p = 0.002) and with larger tumors (4.35cm vs 2.33cm, p < 0.001) than AMP patients (n = 46). DUO patients had a higher rate of surgical complications (68% vs 41%, p = 0.01) with a trend for more pancreatic fistulas (36% vs 20%, p = 0.08). There was no difference in median overall survival between groups. Factors positively influencing survival included Caucasian race (p = 0.02) and normal CA19-9 level at diagnosis (p = 0.01). Tumor factors negatively influencing survival included positive lymph nodes (p = 0.04), lymphovascular invasion (p = 0.001), and perineural invasion (p = 0.02). Within AMP, the PB subtype presented at higher T-stage (p = 0.01) and with more positive lymph nodes (p = 0.03) than IT. There was no difference in survival between subtypes. Majority received adjuvant chemotherapy (88.8% in AMP, 76.3% in DUO), fewer received adjuvant radiotherapy (23.3% in AMP, 30% in DUO), but no survival difference was seen. Conclusions: DUO presents with larger tumors and higher T-stage than AMP and is associated with more surgical complications. The PB phenotype has more advanced pathologic features than IT. No survival difference was seen between anatomic locations or subtypes. Better surgical and chemotherapeutic strategies may be needed to overcome high risk features. Longer follow-up with more patients is needed to confirm these findings.
- 1 February 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34  (4_suppl) , 362
Comparative analysis of resected duodenal and ampullary adenocarcinoma.
362 Background: Duodenal and ampullary adenocarcinomas are rare gastrointestinal cancers that share similar anatomic location and treatment strategy. We report a single-institution experience regarding the association between clinicopathologic features, treatment, and survival outcomes. Methods: A retrospective review of all patients resected with curative intent for duodenal adenocarcinoma (DUO) between 2005-2015 and ampullary adenocarcinoma (AMP) between 2011-2015 at VMMC was performed. For AMP, histologic subtyping into intestinal (IT) and pancreatobiliary (PB) phenotypes was determined. Demographic and clinicopathologic parameters were compared between DUO and AMP patients using Chi-square test. Overall survival was calculated using Kaplan-Meier analysis and prognostic factors were identified by univariate Cox regression. Results: Patients with DUO (n = 44) presented at higher T-stage (p = 0.002) and with larger tumors (4.35cm vs 2.33cm, p < 0.001) than AMP patients (n = 46). DUO patients had a higher rate of surgical complications (68% vs 41%, p = 0.01) with a trend for more pancreatic fistulas (36% vs 20%, p = 0.08). There was no difference in median overall survival between groups. Factors positively influencing survival included Caucasian race (p = 0.02) and normal CA19-9 level at diagnosis (p = 0.01). Tumor factors negatively influencing survival included positive lymph nodes (p = 0.04), lymphovascular invasion (p = 0.001), and perineural invasion (p = 0.02). Within AMP, the PB subtype presented at higher T-stage (p = 0.01) and with more positive lymph nodes (p = 0.03) than IT. There was no difference in survival between subtypes. Majority received adjuvant chemotherapy (88.8% in AMP, 76.3% in DUO), fewer received adjuvant radiotherapy (23.3% in AMP, 30% in DUO), but no survival difference was seen. Conclusions: DUO presents with larger tumors and higher T-stage than AMP and is associated with more surgical complications. The PB phenotype has more advanced pathologic features than IT. No survival difference was seen between anatomic locations or subtypes. Better surgical and chemotherapeutic strategies may be needed to overcome high risk features. Longer follow-up with more patients is needed to confirm these findings.
- 1 February 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34  (4_suppl) , 321
Pattern of CA19-9 response to neoadjuvant chemotherapy in locally advanced, borderline resectable pancreatic cancer to predict progression.
321 Background: As neoadjuvant therapy of locally advanced, borderline resectable pancreatic cancer (BRPC) is becoming more widely utilized; better indicators of progression are needed to help guide therapeutic decisions. The aim of this study is to determine if CA19-9 response during treatment predicts disease progression. Methods: A retrospective review was performed on all patients with BRPC (by AHPBA/SSO consensus criteria) between 2008-2015 who received 24 weeks of neoadjuvant gemcitabine and docetaxel. Patients with medical comorbidities limiting treatment completion were excluded. Serum CA19-9 levels were checked at baseline and every 3 weeks while on therapy. A normal CA19-9 level was defined as < 37.5 units/mL and levels with concomitant biliary obstruction were censored. CA19-9 response was analyzed as a predictor of disease progression, recurrence, and survival. Results: Eighty patients were included with a mean of 11 CA19-9 levels checked per patient during treatment. Thirty-two (40%) progressed on treatment (18 local and 14 distant) and 48 (60%) were resected (79% R0). CA19-9 responses were categorized into 5 groups: 1) Always normal [n = 13]; 2) Increasing [n = 3]; 3) Slow decline [n = 7]; 4) Rapid decline with plateau [n = 41]: and 5)Rapid decline with late rise [n = 16]. Univariate logistic regression analysis found that a final CA19-9 decline > 50% of baseline (OR 0.06, p = <.0001), a normal final CA19-9 (OR 0.08, p = <.0001), pattern group 1 (OR 0.16, p =.0001), and group 4 (OR 0.10, p =.0001) were predictive of non-progression. Baseline or maximum CA19-9 levels were not predictive of progression. All patients in group 2 progressed; none were resected. Patients in pattern group 5 that underwent resection had an increased risk of recurrence (HR 12.5, p =.0005). Median overall survival for groups 1-5 were 20.4, 9.3, 20.8, 31.4, and 16.4 months respectively. Conclusions: Patients with measurable CA19-9 levels who do not have rapid decline with sustained low or normal levels should be considered high risk for progression or recurrence and alternative treatment strategies should be entertained prior to curative resection.
- 1 February 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34  (4_suppl) , 321
Pattern of CA19-9 response to neoadjuvant chemotherapy in locally advanced, borderline resectable pancreatic cancer to predict progression.
321 Background: As neoadjuvant therapy of locally advanced, borderline resectable pancreatic cancer (BRPC) is becoming more widely utilized; better indicators of progression are needed to help guide therapeutic decisions. The aim of this study is to determine if CA19-9 response during treatment predicts disease progression. Methods: A retrospective review was performed on all patients with BRPC (by AHPBA/SSO consensus criteria) between 2008-2015 who received 24 weeks of neoadjuvant gemcitabine and docetaxel. Patients with medical comorbidities limiting treatment completion were excluded. Serum CA19-9 levels were checked at baseline and every 3 weeks while on therapy. A normal CA19-9 level was defined as < 37.5 units/mL and levels with concomitant biliary obstruction were censored. CA19-9 response was analyzed as a predictor of disease progression, recurrence, and survival. Results: Eighty patients were included with a mean of 11 CA19-9 levels checked per patient during treatment. Thirty-two (40%) progressed on treatment (18 local and 14 distant) and 48 (60%) were resected (79% R0). CA19-9 responses were categorized into 5 groups: 1) Always normal [n = 13]; 2) Increasing [n = 3]; 3) Slow decline [n = 7]; 4) Rapid decline with plateau [n = 41]: and 5)Rapid decline with late rise [n = 16]. Univariate logistic regression analysis found that a final CA19-9 decline > 50% of baseline (OR 0.06, p = <.0001), a normal final CA19-9 (OR 0.08, p = <.0001), pattern group 1 (OR 0.16, p =.0001), and group 4 (OR 0.10, p =.0001) were predictive of non-progression. Baseline or maximum CA19-9 levels were not predictive of progression. All patients in group 2 progressed; none were resected. Patients in pattern group 5 that underwent resection had an increased risk of recurrence (HR 12.5, p =.0005). Median overall survival for groups 1-5 were 20.4, 9.3, 20.8, 31.4, and 16.4 months respectively. Conclusions: Patients with measurable CA19-9 levels who do not have rapid decline with sustained low or normal levels should be considered high risk for progression or recurrence and alternative treatment strategies should be entertained prior to curative resection.